Melanoma Study
ECOG 1697: Phase III Randomized Study of Four Weeks High Dose IFNa2b in Stage T2bNo, T3a-bNo, and T1-4, N1a,2a (microscopic melanoma)
Protocol ID
08-308
Protocol Description
Interferon has been shown to have some anti-tumor activity in advanced melanoma, and it has also been found to help prevent recurrence of melanoma in patients with advanced stages of melanoma. Interferon α-2b is normally produced by the body's immune system. This substance is now produced in large quantities in laboratories, making it available for treating patients with cancer. The purpose of this study is to compare the benefits of treatment with Interferon to no treatment after surgery to remove malignant melanoma.
Eligibility Criteria
Patients with malignant melanoma
Primary Investigator(s)
- Craig Devoe, MD
Contact Information
Last Update
March 26, 2010How did I get to this page?
Persistent Navigation
- Home
- About Us
- Centers of Excellence
- Our Laboratories
- Research Topics
-
Clinical Trials
- Addiction
- Aging
- Allergies
- Arthritis
- Autoimmune Disease
- Blood Disorders
- Cancer
- Children's Health
- Circulation
- Diabetes
- Ear & Hearing
- Eyes
- Gastrointestinal/Hepatitis
- Genetics
- Heart
- HIV
- Infectious Diseases
- Joints
- Kidney
- Lung
- Lupus
- Men's Health
- Mental Health
- Neurosciences
- Recruitment Registry
- Skin
- Sleep Disorders
- Smoking
- Urinary Tract
- Weight Control
- Women's Health
- Academics
- Resources for Investigators
- Upcoming Events